Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- PU
- Uo
Lists including Brian
Investments
Vuv Analytics
Total Funding: $36M
Alleviant Medical
Total Funding: $74M
Saranas
Total Funding: $13M
Eterneva
Total Funding: $16M
Alkami Technology
Total Funding: $200M
Liquibase
Total Funding: $24M
Favor Delivery
Total Funding: $34M
OrthoAccel Technologies
Total Funding: $51M
Pivot3
Total Funding: $240M
Qualia
Total Funding: $160M
Work Experience
2005
Managing Director
2005
S3 Ventures is the largest venture firm focused on Texas with over $900 million under management. We invest in Seed, Series A and B business technology, healthcare technology and digital experience companies. We have a unique single LP funding model that supports entrepreneurs as they seek to build great companies.
2025
Board of Directors
2025
Endovascular Engineering, Inc. (“E2”), is a mission-driven, venture-backed company focused on the development and deployment of next generation clot removal technologies that target venous thromboembolism.
2024
Board of Directors
2024
Image Without Compromise. The HyperVue Imaging System brings next generation intravascular imaging to your cath lab with powerful images and simplified workflows.
2016
Board of Directors
2016
For enterprises competing in today's application economy, Datical accelerates release cycles by making database deployments as agile as the application.
2014
Board of Directors
2014
VUV makes universal detectors that bring gas analytics out of the dark ages.
2011
Board of Directors
2011
The next generation of online and mobile banking.
2021 - 2024
Board of Directors
2021 - 2024
Saranas invented the Early Bird, the first and only FDA-approved bleed detection system for peri and post-procedural monitoring of endovascular procedures, providing accurate and actionable information before it is too late.
2010 - 2021
Board of Directors
2010 - 2021
Health Benefits Optimization via Software and services enabling the large-scale shift to consumer directed healthcare.
2017 - 2020
Board Of Directors
2017 - 2020
Acessa is a minimally invasive, uterine-sparing solution for fibroids. FDA cleared Acessa addresses all fibroid locations, is outpatient and women are better in days vs. weeks with other methods. Acessa was acquired in August, 2020 by Hologic (Nasdaq:HOLX).
2017 - 2020
Investor
2017 - 2020
Liveoak enables global enterprises to do business with their customers without being in person.